POA
SCMP

Pergamon Offshore Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Pergamon Offshore Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,137
Closed -$241K – 139
2015
Q3 		$241K Buy
+12,137
New +$278K 0.26% 134

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Pergamon Offshore Advisors's SCMP Position: Q4 2015 in Review

Pergamon Offshore Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2015, closing a stake of 12,137 shares — an estimated $241K sold.

Pergamon Offshore Advisors first reported a position in SCMP in Q3 2015 and held it in 1 quarter. The position peaked at $241K in Q3 2015. 149 funds tracked by Wall St. Rank hold SCMP as of Q4 2015.

  • Pergamon Offshore Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Pergamon Offshore Advisors sold 12,137 Sucampo Pharmaceuticals, Inc. shares in Q4 2015, an estimated $241K.
  • Pergamon Offshore Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2015 and held it in 1 quarter.
  • Pergamon Offshore Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $241K in Q3 2015.
  • 149 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2015.

Based on Pergamon Offshore Advisors's 13F filing for Q4 2015.